CA2873094A1 - Prodrugs of anti-platelet agents - Google Patents

Prodrugs of anti-platelet agents Download PDF

Info

Publication number
CA2873094A1
CA2873094A1 CA2873094A CA2873094A CA2873094A1 CA 2873094 A1 CA2873094 A1 CA 2873094A1 CA 2873094 A CA2873094 A CA 2873094A CA 2873094 A CA2873094 A CA 2873094A CA 2873094 A1 CA2873094 A1 CA 2873094A1
Authority
CA
Canada
Prior art keywords
independently
formula
administration
compound
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2873094A
Other languages
English (en)
French (fr)
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellix Bio Pvt Ltd
Original Assignee
Cellix Bio Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2012/053673 external-priority patent/WO2013024376A1/en
Application filed by Cellix Bio Pvt Ltd filed Critical Cellix Bio Pvt Ltd
Publication of CA2873094A1 publication Critical patent/CA2873094A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2873094A 2012-05-07 2013-03-24 Prodrugs of anti-platelet agents Abandoned CA2873094A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1781CH2012 2012-05-07
IN1781/CHE/2012 2012-05-07
IBPCT/IB2012/053673 2012-07-19
PCT/IB2012/053673 WO2013024376A1 (en) 2011-08-16 2012-07-19 Compositions and methods for the treatment of atherothrombosis
PCT/IB2013/052328 WO2013168024A1 (en) 2012-05-07 2013-03-24 Prodrugs of anti-platelet agents

Publications (1)

Publication Number Publication Date
CA2873094A1 true CA2873094A1 (en) 2013-11-14

Family

ID=54193687

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873094A Abandoned CA2873094A1 (en) 2012-05-07 2013-03-24 Prodrugs of anti-platelet agents

Country Status (8)

Country Link
EP (1) EP2847197A4 (https=)
JP (1) JP2015519334A (https=)
CN (1) CN104379589A (https=)
AU (1) AU2013257745A1 (https=)
CA (1) CA2873094A1 (https=)
SG (1) SG11201407307YA (https=)
WO (1) WO2013168024A1 (https=)
ZA (1) ZA201408064B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201407328TA (en) * 2012-07-03 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of moderate to severe pain
CN119033782B (zh) * 2020-07-29 2025-04-25 上海柯君医药科技有限公司 抗血小板药物和其用途
CN114507157B (zh) * 2020-11-17 2023-03-24 沧州维智达美制药有限公司 一种利用氯乙腈制备溴乙腈的方法
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858734B2 (en) * 2003-04-23 2005-02-22 Rhodia Pharma Solutions Inc. Preparation of (S)-Clopidogrel and related compounds
CN101123878A (zh) * 2003-07-29 2008-02-13 信号研发控股有限责任公司 氨基酸前药
EP1889835A4 (en) * 2005-05-27 2010-04-28 Daiichi Sankyo Co Ltd CYCLIC AMINE DERIVATIVE WITH SUBSTITUTED ALKYL GROUP
KR100990949B1 (ko) * 2008-06-09 2010-10-29 엔자이텍 주식회사 클로피도그렐 및 그의 유도체의 제조방법
CN102002053A (zh) * 2009-09-02 2011-04-06 陕西合成药业有限公司 用于治疗的四氢噻吩并吡啶衍生物
CN102336767A (zh) * 2011-07-11 2012-02-01 华东理工大学 制备高纯度手性α-取代-6,7-二氢噻吩并[3,2-c]吡啶衍生物的方法
WO2013024376A1 (en) * 2011-08-16 2013-02-21 Mahesh Kandula Compositions and methods for the treatment of atherothrombosis
US9525998B2 (en) * 2012-01-06 2016-12-20 Qualcomm Incorporated Wireless display with multiscreen service
JP6097766B2 (ja) * 2012-01-27 2017-03-15 インターデイジタル パテント ホールディングス インコーポレイテッド マルチキャリアベースおよび／または疑似照合ネットワークにおいてｅｐｄｃｃｈを提供するためのシステムおよび／または方法
WO2013167985A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
SG11201407317SA (en) * 2012-05-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for suppression of carbonic anhydrase activity
WO2013167987A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of diabetes
JP2015526385A (ja) * 2012-05-08 2015-09-10 セリックスビオ プライヴェート リミテッド てんかんの治療のための組成物及び方法
CA2872976A1 (en) * 2012-05-08 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
SG11201407328TA (en) * 2012-07-03 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of moderate to severe pain

Also Published As

Publication number Publication date
SG11201407307YA (en) 2014-12-30
AU2013257745A1 (en) 2014-11-27
JP2015519334A (ja) 2015-07-09
WO2013168024A1 (en) 2013-11-14
EP2847197A1 (en) 2015-03-18
ZA201408064B (en) 2016-04-28
CN104379589A (zh) 2015-02-25
EP2847197A4 (en) 2015-11-04

Similar Documents

Publication Publication Date Title
WO2013168022A1 (en) Compositions and methods for treating atherothrombosis
CA2914461A1 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014087367A2 (en) Compositions and methods for the treatment of neurological diseases and its associated complications
WO2014068463A2 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2014087307A2 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
CA2873094A1 (en) Prodrugs of anti-platelet agents
AU2013257706A1 (en) Compositions and methods for the treatment of neurological disorders
WO2014080307A2 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
AU2013257707A1 (en) Compositions and methods for the treatment of epilepsy
WO2014195850A2 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
WO2014068506A2 (en) Compositions and methods for the treatment of autoimmune diseases
US9242939B2 (en) Compositions and methods for the treatment of respiratory disorders
WO2018087605A1 (en) Compositions and methods for the treatment of gastrointestinal polyps
WO2014118649A2 (en) Compositions and methods for the treatment of cardiovascular diseases
WO2014057439A2 (en) Compositions and methods for the treatment of neurological diseases and its associated complications
US20150087697A1 (en) Compositions and methods for the treatment of muscle pain
US9175008B1 (en) Prodrugs of anti-platelet agents
WO2017208088A2 (en) Compositions and methods for the treatment of parkinson's disease
US9290486B1 (en) Compositions and methods for the treatment of epilepsy
WO2014080309A2 (en) Compositions and methods for the treatment of inflammation and lipid disorders
WO2017037661A1 (en) Compositions and methods for the treatment of parkinson's disease
WO2013179153A1 (en) Compositions and methods for treatment of neurological degenerative disorders and neurological diseases
WO2014147541A2 (en) Compositions and methods for the treatment of peptic ulcers and gastrointestinal diseases
WO2015028956A1 (en) Compositions and methods for the treatment of fatty acid oxidation disorders
WO2014122575A2 (en) Fatty acid conjugates for the treatment of inflammation and metabolic diseases

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20180326